Study title: A single dose, randomised, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of FormoterolHFA pMDI 12 mg per actuation administered by means of a "spacer"device (AeroChamber PlusTM) with that of Formoterol-HFA pMDI 12 mg per actuation in 5 to 12 yesar old children with persistent moderate to severe asthma.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases | |||||
| Brands: | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: FORMOTEROL | |||||
| ATC code: R03AC13 | |||||
| Document link: CCD-0602-RS-0004 (Synopsis).doc | |||||
| Document date: 2015-03-02 | |||||
| Study number: DM-PR-3301-003-05 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |